UTSW Heme/Onc & Clinical Informatics Fellow 📊 Breast+GI+Sarcoma Oncology 🩺 #Rstats @thecodingdocs 💻 REDCap Coder 🧢 UMiami Med🌴 UCSB 🌊 Personal Opinions 🤠
Dallas, TX
Joined August 2021
- Tweets3.7K
- Following987
- Followers1.5K
- Likes13.4K
Pinned Tweet
📣 Introducing {REDCapSync} and {RosyREDCap} @TheCodingDocs. Thanks for the @RConsortium and the @r_medicine conference for giving me the platform to share the culmination of years of experience in #rstats data pipelines.
thecodingdocs.github.io/REDC…
Brandon Rose, MD, MPH retweeted
6 years ago, I had the chance to publish a paper that would end up changing my academic life
It was a review article exploring the surprising activity of certain ADCs in “HER2-low” breast cancer, a newly emerging entity whose relevance was still uncertain.
We tried to connect the dots, asking if HER2-low was a subtype vs just a target, wondering whether this concept could one day translate into meaningful benefits for patients.
6 years later, that article has reached 1,000 citations. My career has gifted me more than I could ever have imagined. More importantly, what was once an intriguing scientific observation has become a clinical reality: countless patients with HER2-low breast cancer now live longer thanks to T-DXd.
A reminder of how far science can take us in just a few years.
Grateful to everyone who has been part of this journey!
ascopubs.org/doi/10.1200/JCO…
Brandon Rose, MD, MPH retweeted
Thousands of clinical trials are looking for patients.
Epic AI helps match trials with the right patients, giving them a new option for treatment.
Since this spring, more than 60 organizations have started using it to automatically check study criteria against what’s already in the chart. Study teams can quickly see who may be a fit and invite them right in MyChart.
Brandon Rose, MD, MPH retweeted
⚡️ Concomitant publications demand extra effort from authors, reviewers and editorial team, but deliver what matters most: getting outstanding science out ASAP to advance cancer care.
Glad to have handled 2 outstanding @ESMO_Open concomitant pubs by @kazuki_nozawa & @drsarahsam!
Concomitant publications at #ESMO26: new data moving swiftly from the podium to the peer-reviewed journals.
@Annals_Oncology @ESMO_Open @NEJM @NatureMedicine @TheLancet @TheLancetOncol @Nature @JAMA_current
Brandon Rose, MD, MPH retweeted
Earlier this month, Heather McArthur, M.D., M.P.H., FASCO, and Carlos L. Arteaga, M.D., represented #UTSW and our Breast Cancer Program at the @BCRFcure 2026 Symposium & Awards Luncheon in New York, bringing together leaders in breast cancer research. @hmcarthur @CarlosArteagaMD
ALT Two medical professionals from UT Southwestern. On the left, a female is wearing a white coat and smiling, with visible credentials. On the right, a man is wearing a suit and standing with his hands together in the front of him.
ALT A large group of people stands on a stage in formal attire at an event. A screen above displays the pink ribbon logo of the Breast Cancer Research Foundation.
Brandon Rose, MD, MPH retweeted
Congratulations to Fabiana Napolitano, M.D., Ph.D., Nisha Unni, M.D., & @CarlosArteagaMD, on their new @JCIInsight publication, “PI3K Signaling in Breast Cancer: Therapeutic Advances vs. Adaptive Resistance,” advancing precision medicine in breast cancer.
bit.ly/4dO9URe
ALT This image features three headshots below a journal cover titled "The Journal of Clinical Investigation" and the research topic "PI3K signaling in breast cancer: therapeutic advances versus adaptive resistance." The authors named are Fabiana Napolitano, Nisha Unni, and Carlos L. Arteaga. In the bottom corner, the UT Southwestern National Cancer Institute logo is displayed.
Question for the ESMO breast cancer crowd: what would be a good study to present to heme/onc fellow academic half day that will change standard of care significantly ? @PTarantinoMD @stolaney1 and others!
Brandon Rose, MD, MPH retweeted
Primary results from BRIDGET ph2 trial presented by @drsarahsam and published in @ESMO_Open. Adding tucatinib to HP after an isolated intracranial PD led to impressively long PFS (59% free from PD or death at 18mo!!). Reasonable strategy from next Monday in TKI-naive patients.
Brandon Rose, MD, MPH retweeted
Presented at #ESMO26:
In patients with 𝘌𝘎𝘍𝘙-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed. Full phase 3 SAFFRON trial results: nej.md/4hXdueb
@myESMO
ALT A graph showing progression-free survival in the full analysis population.
Brandon Rose, MD, MPH retweeted
Tucatinib added to HP is a nice option for 1L low volume brain only disease after local therapy.
Particularly in patients with no extracranial disease where the toxicity of ADC is not desired.
#ESMO26
📌 BRIDGET: A phase II trial of tucatinib added to trastuzumab/pertuzumab or ado-trastuzumab emtansine after isolated intracranial progression in patients with advanced HER2-positive breast cancer
✨@drsarahsam
#ESMO26 🇪🇸 @OncoAlert #OncoAlertAF
Brandon Rose, MD, MPH retweeted
The SWITCH trial adds important prospective data on TOPO1 ADC sequencing. Among TOPO1-ADC pretreated pts with MBC, barely any activity was observed with a second TOPO1 ADC, with <10% ORR and <3 mo PFS, despite switching target. Payload cross-resistance dominates. #ESMOAmbassadors
Brandon Rose, MD, MPH retweeted
Switching ADC target does not work. Switching payload does.
Among 60 TOPO1-ADC-pretreated patients with MBC, using a microtubule (MMAE) ADC led to 30% ORR and DoR of 8.8 mo. #ESMO26 #ESMOAmbassadors
Brandon Rose, MD, MPH retweeted
HER2-CR study of MRD in long-term responders to anti HER2 therapy presented by @kazuki_nozawa. Extremely promising association of ctDNA dynamics with outcomes. Concomitant @ESMO_Open publication! #ESMO26 #ESMOAmbassadors
Brandon Rose, MD, MPH retweeted
Significant OS benefit with Sac-TMT vs chemo for highly pretreated mTNBC, consistent with results from ASCENT (SG). Multiple global phase 3 trials ongoing with this Trop2 ADC, which will likely expand its role beyond 🇨🇳 (where it is already approved) #ESMO26 #ESMOAmbassadors
Brandon Rose, MD, MPH retweeted
Presented at #ESMO26:
Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: nej.md/4Bo3liu
@myESMO
ALT A graph from the Original Article " Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” The trial name, OptiTROP-Lung06, is in parentheses after the title. The graph shows progression-free survival as assessed by blinded independent central review. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.
Brandon Rose, MD, MPH retweeted
Trial ongoing! ascopubs.org/doi/10.1200/JCO…
With the first promising data presented at #SABCS25 aacrjournals.org/clincancerr…
TROPION-Breast02, brain mets subgroup at ESMO 2026. First-line Dato-DXd vs chemo in mTNBC, n=61.
CNS PFS 9.5 vs 2.6 mo, HR 0.27. Intracranial ORR 62.5% vs 37.5%. Longest intracranial response about 27 mo.
In TNBC, brain mets come early and we usually treat them locally first. This makes me ask whether a patient with small asymptomatic lesions could start Dato-DXd and defer /combine SRS
Not ready for clinic. This is a post hoc subgroup, n=30 with untreated brain mets. And even on Dato-DXd, median OS was 11.6 mo with brain mets vs 23.7 mo without. The CNS benefit is real; the prognosis is still poor. The answer needs a dedicated CNS trial. #bcsm #ESMO26
@myESMO
Brandon Rose, MD, MPH retweeted
Quite a remarkable ESMO. This conference keeps raising the bar, year by year! #ESMO26 #ESMOAmbassadors
Science takes centre stage once again as Presidential Symposium II welcomes a packed auditorium at #ESMO26. ✨
Brandon Rose, MD, MPH retweeted
For the final act of CheckMate 8HW, we finally have the significant OS data the doubters have been asking for.
What happens when you have a great treatment and an even better one for a study (and almost everyone crosses over)? You have to wait a really, really long time for OS. Also, some thoughts on splitting the alpha I won’t get into here.
Nivo/ipi vs nivo alone vs chemo, MSI-H/dMMR mCRC. Final OS analysis.
Response rate 72% with nivo/ipi, 58% with nivo alone.
Median OS still not reached.
OS HR 0.66 for nivo/ipi over nivo, statistically significant.
77% of nivo/ipi patients alive at 5 years.
Three out of four patients alive at five years. In metastatic colorectal cancer. 🤯
Not even going to talk about the chemo arm. It's clearly worse, and there is never a time to give chemo in MSI-H unless someone has extreme, active autoimmune disease. “Debulking” is absolute nonsense.
Bottom line: the doubters got their OS. Nivo/ipi is the first-line standard for MSI-H mCRC.
Next steps: how do we decide length of therapy, and how do we manage oligometastatic progression?
#ESMO26
@OncoAlert @TheGutOncLab @OncoAlert
Brandon Rose, MD, MPH retweeted
Important data presented at #ESMO2026
TROPION-Breast02 | 1L mTNBC with brain metastases
• Median CNS PFS: 9.5 vs 2.6 months (HR 0.27)
• Intracranial ORR: 62.5% vs 37.5%
Dato-DXd showed great activity, regardless of prior CNS-directed therapy in TNBC
@OncoAlert
Brandon Rose, MD, MPH retweeted
#ESMO26 | TALENT
Neoadjuvant T-DXd showed very low pCR rates in HR+/HER2-low early breast cancer:
- T-DXd: 7%
- T-DXd + anastrozole: 3%
- T-DXd → chemotherapy: 9%
We should remember that pCR is a limited surrogate endpoint in HR+ disease. However, these results do not support T-DXd as an alternative to standard neoadjuvant chemotherapy.
Moreover, given the heterogeneity of HER2-low disease, I find it unsurprising that the success of T-DXd in the metastatic setting does not translate into similar outcomes in early-stage disease, despite the lower tumor burden.
Brandon Rose, MD, MPH retweeted
POP-DURVA
2 cycles of durvalumab for preop TNBC (T1N0)
n=78
pCR: 1.4%
@OncoAlert #ESMO26
